Cytoskeleton and paclitaxel sensitivity in breast cancer: the role of beta-tubulins.
about
The fate of chemoresistance in triple negative breast cancer (TNBC)Beyond taxanes: the next generation of microtubule-targeting agentsThe miR-200 and miR-221/222 microRNA families: opposing effects on epithelial identityHigh expression of class III β-tubulin predicts good response to neoadjuvant taxane and doxorubicin/cyclophosphamide-based chemotherapy in estrogen receptor-negative breast cancerMicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agentsCancer cells acquire mitotic drug resistance properties through beta I-tubulin mutations and alterations in the expression of beta-tubulin isotypesApproaching solid tumor heterogeneity on a cellular basis by tissue proteomics using laser capture microdissection and biological mass spectrometryP-gp activity is a critical resistance factor against AVE9633 and DM4 cytotoxicity in leukaemia cell lines, but not a major mechanism of chemoresistance in cells from acute myeloid leukaemia patientsClass III beta-tubulin expression and in vitro resistance to microtubule targeting agents.End-binding protein 1 stimulates paclitaxel sensitivity in breast cancer by promoting its actions toward microtubule assembly and stabilityDecreased levels of baseline and drug-induced tubulin polymerisation are hallmarks of resistance to taxanes in ovarian cancer cells and are associated with epithelial-to-mesenchymal transitionThe design and discovery of water soluble 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multitargeted receptor tyrosine kinase inhibitors and microtubule targeting antitumor agentsLigand-receptor interaction between triterpenoids and the 11beta-hydroxysteroid dehydrogenase type 2 (11betaHSD2) enzyme predicts their toxic effects against tumorigenic r/m HM-SFME-1 cellsCircadian rhythms in gene expression: Relationship to physiology, disease, drug disposition and drug action.A target based approach identifies genomic predictors of breast cancer patient response to chemotherapy.Chemotherapy resistance in metastatic breast cancer: the evolving role of ixabepiloneSynthesis and discovery of water-soluble microtubule targeting agents that bind to the colchicine site on tubulin and circumvent Pgp mediated resistance2-Amino-4-methyl-5-phenylethyl substituted-7-N-benzyl-pyrrolo[2,3-d]pyrimidines as novel antitumor antimitotic agents that also reverse tumor resistance.The prognostic role of the class III β-tubulin in non-small cell lung cancer (NSCLC) patients receiving the taxane/vinorebine-based chemotherapy: a meta-analysis.Development of a rapid and sensitive UPLC-MS/MS assay for the determination of TM-2 in beagle dog plasma and its application to a pharmacokinetic study.Synthesis and biological activities of (R)- and (S)-N-(4-Methoxyphenyl)-N,2,6-trimethyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-aminium chloride as potent cytotoxic antitubulin agents.Advancements in the Treatment of Metastatic Breast Cancer (MBC): The Role of Ixabepilone.Lentinan exerts synergistic apoptotic effects with paclitaxel in A549 cells via activating ROS-TXNIP-NLRP3 inflammasomeNovel water-soluble substituted pyrrolo[3,2-d]pyrimidines: design, synthesis, and biological evaluation as antitubulin antitumor agentsUse of comparative proteomics to identify potential resistance mechanisms in cancer treatment.Pharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase I trial in patients with advanced solid tumors: a California Cancer Consortium trial.Altered TUBB3 expression contributes to the epothilone response of mitotic cells.Circadian variations in rat liver gene expression: relationships to drug actions.Tubulin-β-III overexpression by uterine serous carcinomas is a marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to epothilones.Neoadjuvant doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early stage breast cancer and evaluation of βIII-tubulin expression as a predictive marker.Tubulin targets in the pathobiology and therapy of glioblastoma multiforme. I. Class III beta-tubulin.Class III β-tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin/paclitaxelModelling the microtubule: towards a better understanding of short-chain fatty acid molecular pharmacology.Epothilones in the treatment of ovarian cancer.Class III b-tubulin overexpression in gynecologic tumors: implications for the choice of microtubule targeted agents?Tubulin: an example of targeted chemotherapy.Design, Synthesis, and Preclinical Evaluation of 4-Substituted-5-methyl-furo[2,3-d]pyrimidines as Microtubule Targeting Agents That Are Effective against Multidrug Resistant Cancer Cells.Effect of CH-35, a novel anti-tumor colchicine analogue, on breast cancer cells overexpressing the βIII isotype of tubulin.Molecular diagnosis and molecular profiling to detect treatment-resistant ovarian cancer.Predictors of chemotherapy efficacy in non-small-cell lung cancer: a challenging landscape.
P2860
Q26775232-07835BF7-FC9B-43E7-8333-AA1424DF6B60Q26865369-1AFBACDC-DAFE-4739-ACEB-094D903C1846Q27010233-637CD9EB-27E9-48F1-8E9C-F7C165B9C30DQ27851983-CD827202-D36C-4BD4-A7DD-00A2ED6EFA3AQ28244659-C90D07BA-4C6D-4F8D-9232-BEDF411165FEQ28475393-617F845F-DB5B-43E2-9118-155F8C94E955Q33418010-0FDF4EE4-2F0F-4D2F-8E5E-77910B2604B7Q33472987-F4FEE77E-5065-4ACA-A86C-02B0BD89C92AQ33630855-32CF3800-DA62-47A1-8300-50321A795ACEQ33632830-62F071DF-FD89-4A8C-AF9C-CE46FC473C64Q33829740-B648EF0D-B84D-4843-A293-276ED5FFA5CAQ33872751-26DD9229-0882-47DA-BA37-CA5162AD2D3AQ34006732-E5475768-7A86-4F3A-8661-9D2EC00F9B3DQ34069298-BF32346E-C9DD-4485-ABEC-ED387BFE1233Q34266467-E0B0EA62-D11F-4E42-9098-1C66EE8807B5Q34274930-34AC6BBA-FCB2-4DBF-851C-287DEEF6D0A9Q34336551-12D6F304-9E85-4736-9F08-AE1CC92D4261Q35110635-8EF0C6FD-1D97-4F0A-A8EE-2960D6F2E5F0Q35140489-5578E1B7-F6F4-4F1E-B62D-55E271E939CEQ35168711-1CBF1E5A-A51E-4B44-83FE-4C82583DFD84Q35253350-3449AEAF-8E4D-47AC-AB4E-1FB6EB488ED3Q35975007-C2CBEC97-464D-4586-8B8B-2C356FEF4A04Q35995102-36DA73E0-48B8-44A6-AD62-D8BCA4BADFBBQ36328577-22AB23EC-F18D-44FC-9077-CD8CF2787DB6Q36388185-A92CD00E-BA3D-470D-B901-65E4997EBDC1Q36411072-C3167C13-98AB-47BB-A7DC-2CCAD28FCE4DQ36557893-E33500C5-55C8-4AC8-ACCB-D408D62BD3AFQ36923742-2B66505A-96C0-429A-BFFF-8B6946F6C5CEQ36980135-D2121D78-F537-4D72-92E4-AD1052746518Q37038455-2C46572D-E109-4463-9735-386E4AD103FBQ37570220-F42F55E5-0B16-4B63-9F31-F21FC4D98C78Q37625835-CEF789BC-973A-41EA-8B35-75E39411BE56Q37833936-158AE8EE-72E6-4625-AF14-601970C72D2DQ37861204-DC5D56D7-53E1-48C4-B8C5-DD609B3401ECQ38069185-F035BF6D-8E13-4CE4-9F89-9BD163A97BB9Q38086872-DB1D4610-0FC5-4A4D-A32D-81F6A7E9E9C6Q38769177-27D12B43-3C3A-419E-979C-FFFB7D44E4D3Q38810389-B50394EA-BFA9-4C19-9EFD-E2D323249D3AQ38832323-E5722CAC-C898-4C3F-8D1A-15B909402D2BQ38922208-DC13783A-FB69-45F9-947B-554B4F4B42A2
P2860
Cytoskeleton and paclitaxel sensitivity in breast cancer: the role of beta-tubulins.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Cytoskeleton and paclitaxel sensitivity in breast cancer: the role of beta-tubulins.
@en
type
label
Cytoskeleton and paclitaxel sensitivity in breast cancer: the role of beta-tubulins.
@en
prefLabel
Cytoskeleton and paclitaxel sensitivity in breast cancer: the role of beta-tubulins.
@en
P2093
P2860
P356
P1476
Cytoskeleton and paclitaxel sensitivity in breast cancer: the role of beta-tubulins.
@en
P2093
Agnese Latorre
Angelo Paradiso
Annalisa Chiriatti
Antonia Bellizzi
Christopher Thomssen
Francesco Schittulli
Francesco Zito
Maria Kavallaris
Nancy Kendzierski
Rosanna Lacalamita
P2860
P304
P356
10.1002/IJC.22557
P577
2007-05-01T00:00:00Z